Il DynamX Bioadaptor di Elixir Medical dimostra un miglioramento significativo rispetto ai moderni stent a rilascio di farmaci nei pazienti affetti da sindrome coronarica acuta e sottogruppi di lesioni complesse dopo sei mesi
October 28, 2024 14:00 ET
|
Elixir Medical Corporation
Il DynamX Bioadaptor di Elixir Medical dimostra un miglioramento significativo rispetto ai moderni stent a rilascio di farmaci nei pazienti affetti da sindrome coronarica acuta e sottogruppi di...
Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
October 28, 2024 14:00 ET
|
Elixir Medical Corporation
Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months ...
ESC Kongress 2024: INFINITY-SWEDEHEART-Studie mit dem DynamX-Bioadaptor von Elixir Medical erreicht primären Endpunkt und klinische Ergebnisse bestätigen einzigartigen Wirkmechanismus
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
ESC Kongress 2024: INFINITY-SWEDEHEART-Studie mit dem DynamX-Bioadaptor von Elixir Medical erreicht primären Endpunkt und klinische Ergebnisse bestätigen einzigartigen Wirkmechanismus Größter...
Congreso ESC 2024: El ensayo INFINITY-SWEDEHEART del bioadaptador DynamX de Elixir Medical alcanza el criterio de valoración principal y los resultados clínicos confirman su exclusivo mecanismo de acción
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
Congreso ESC 2024: El ensayo INFINITY-SWEDEHEART del bioadaptador DynamX de Elixir Medical alcanza el criterio de valoración principal y los resultados clínicos confirman su exclusivo mecanismo de...
Congresso ESC 2024: lo studio INFINITY-SWEDEHEART relativo al DynamX Bioadaptor di Elixir Medical soddisfa l’endpoint primario e i risultati clinici confermano un meccanismo d’azione unico
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
Congresso ESC 2024: lo studio INFINITY-SWEDEHEART relativo al DynamX Bioadaptor di Elixir Medical soddisfa l’endpoint primario e i risultati clinici confermano un meccanismo d’azione unico — La più...
Congrès ESC 2024 : L’essai INFINITY-SWEDEHEART portant sur le DynamX Bioadaptor d’Elixir Medical satisfait au critère d’évaluation principal et les résultats cliniques confirment un mécanisme d'action unique
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
Congrès ESC 2024 : L’essai INFINITY-SWEDEHEART portant sur le DynamX Bioadaptor d’Elixir Medical satisfait au critère d’évaluation principal et les résultats cliniques confirment un mécanisme d'action...
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action —Largest randomized data set to...
Le système coronaire DynamX Bioadaptor à élution de sirolimus d'Elixir Medical a reçu la « Breakthrough Device Designation » de la FDA
July 29, 2024 02:00 ET
|
Elixir Medical Corporation
Le système coronaire DynamX Bioadaptor à élution de sirolimus d'Elixir Medical a reçu la « Breakthrough Device Designation » de la FDA pour le traitement de la cardiopathie ischémique...
Das DynamX Sirolimus-Eluting Coronary Bioadaptor System von Elixir Medical erhält die FDA-Auszeichnung als bahnbrechendes Implantat
July 29, 2024 02:00 ET
|
Elixir Medical Corporation
Das DynamX Sirolimus-Eluting Coronary Bioadaptor System von Elixir Medical erhält die FDA-Auszeichnung als bahnbrechendes Implantat zur Behandlung symptomatischer ischämischer Herzkrankheit ...
Elixir Medical’s DynamX Sirolimus-Eluting coronary bioadaptor system receives US FDA Breakthrough Device Designation
July 29, 2024 02:00 ET
|
Elixir Medical Corporation
Elixir Medical's DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease Designation recognizes the...